- Thinly traded micro cap OncoCyte (NASDAQ:OCX) is up 56% after hours on average volume in response to its announcement that a study of its DetermaVu lung cancer test based on Next Gen Sequencing (NGS), an enhanced algorithm and incorporating new biomarkers showed a level of performance beyond expectations.
- The company says the use of the NGS platform may enable decentralized operations beyond its CLIA lab and the development of a CE-Mark'd test kit that could be distributed in Europe.
- It plans to further test the new biomarkers on a broader set of samples aimed at selecting the best biomarker panel and algorithm. It expects to complete the expanded R&D validation study by year-end and the clinical validation study in H1 2019.